Bausch Health Companies Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount
Bausch Health Companies Inc. (BHC) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount of $23.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-02-19
- Bausch Health Companies Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for the quarter ending 2024-12-31 was $16.00M.
- Bausch Health Companies Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2025 was $23.00M, a 21.05% increase from fiscal 2024.
- Bausch Health Companies Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2024 was $19.00M, a 0.00% change from fiscal 2023.
- Bausch Health Companies Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2023 was $19.00M, a 0.00% change from fiscal 2022.
- Bausch Health Companies Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2022 was $19.00M, a 111.11% increase from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 3 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 9 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month as first filed |
|---|---|---|---|---|
| 2025-12-31 | $23.00M 10-K · filed 2026-02-19 | |||
| 2024-12-31 | $16.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $19.00M 10-K · filed 2026-02-19 | ||
| 2024-09-30 | $3.00M 10-Q · filed 2025-10-30 | |||
| 2023-12-31 | $19.00M 10-K · filed 2026-02-19 | |||
| 2022-12-31 | $19.00M 10-K · filed 2025-02-20 | |||
| 2021-12-31 | $9.00M 10-K · filed 2024-02-22 | |||
| 2020-12-31 | $9.00M 10-K · filed 2023-02-23 | |||
| 2019-12-31 | $7.00M 8-K · filed 2022-05-11 | |||
| 2018-12-31 | $10.00M 8-K · filed 2021-05-04 | |||
| 2017-12-31 | $37.00M 10-K · filed 2020-02-19 | |||
| 2016-12-31 | $30.00M 10-K · filed 2019-02-20 | |||
| 2015-12-31 | $4.00M 8-K · filed 2018-08-10 | $4.40M 10-K · filed 2016-04-29 | ||
| 2014-12-31 | $20.00M 10-K · filed 2017-03-01 | $19.80M 10-K · filed 2015-02-25 | ||
| 2013-12-31 | $13.10M 10-K · filed 2016-04-29 | $13.10M 10-K · filed 2014-02-28 | ||
| 2012-12-31 | $6.30M 10-K · filed 2015-02-25 | $6.26M 10-K · filed 2013-02-28 | ||
| 2011-12-31 | $14.04M 10-K · filed 2014-02-28 | |||
| 2010-12-31 | $8.02M 10-K · filed 2013-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |